Innoviva to Participate in Upcoming Investor Conferences
INVABURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: Citi's 2025 Biopharma Back to School Conference Format: Fir
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
INVAWALTHAM, Mass.--(BUSINESS WIRE)--Prix Galien Award 2025
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
INVABURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2025, and highlighted select corporate progress and achievements. “Innoviva continued to deliver i
Innoviva Says FDA Grants Priority Review For Zoliflodacin New Drug Application For Treatment Of Uncomplicated Gonorrhea And Assigns Target PDUFA Date of December 15
INVAFDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
INVAWALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
INVAWALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance For Zoliflodacin, An Oral Antibiotic For Uncomplicated Gonorrhea in Adults
INVAInnoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
INVAWALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adul
Innoviva Announces U.S. Launch Of Zevtera, An FDA Approved Advanced Generation Cephalosporin For MRSA SAB Since 2006, To Treat Three Types of Bacterial Infections
INVABasilea And Innoviva Launch Zevtera In U.S. As First MRSA-Active Antibiotic Approved For Staph Bacteremia In Over A Decade
INVAInnoviva Q1 EPS $(0.74) Misses $0.38 Estimate, Sales $88.63M Beat $82.67M Estimate
INVARep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know
INVAScotiabank Initiates Coverage On Innoviva with Sector Outperform Rating, Announces Price Target of $55
INVAInnoviva Q4 EPS $0.26 Misses $0.37 Estimate, Sales $91.81M Beat $86.80M Estimate
INVAZai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China
INVA